What is a cardiovascular calcium test

The short version: a coronary calcium test is a CT scan that measures how much calcified plaque has built up in the heart's arteries, and that number strongly predicts your future risk of heart attack or death, independent of cholesterol and blood pressure.

A coronary artery calcium (CAC) test is a noninvasive CT scan that does not require dye. It picks up speck-sized calcium deposits in the wall of the coronary arteries. The machine sums them into a score, usually the Agatston score, where zero means no detectable calcium. The higher the number, the more plaque has settled into the artery wall.

This test is one of the most well-validated tools in cardiac medicine. In the MESA study of nearly 7,000 people across four ethnic groups, a CAC score above 300 raised the risk of a major heart attack or death by about 7-fold compared to a score of zero [15]. The risk rose steadily: a score between 1 and 100 carried a 3.9-fold higher risk, and between 101 and 300 carried roughly a 7-fold higher risk [15].

Another large study of over 5,600 people tracked for 37 months found that the calcium score predicted events even when standard risk factors like cholesterol and blood pressure were taken into account [14]. A score of 400 or more on a low-dose CT scan from a lung cancer screening program carried a nearly 3-fold higher risk of a cardiovascular event and a 3.7-fold higher risk of all-cause death [8]. In chronic kidney disease patients, the average CAC score was 2,370, and higher scores tracked closely with the number of blocked vessels seen on angiography [4].

The score is not perfect. The same plaque can be either stable or vulnerable, and the test sees only the calcium, not the soft, rupture-prone part of the plaque [17]. Reproducibility varies: repeat scans can differ by about 18-27% between runs [6, 9]. And a zero score does not mean zero risk, though the risk is low.

The vast majority of the research on CAC scoring was funded by the National Institutes of Health, not by device or drug manufacturers. The MESA trial, the largest and most rigorous, was published in the New England Journal of Medicine and has been independently replicated [7, 8, 16]. There are no liability shields here, no vaccine-like regulatory capture of the evidence base. The test is diagnostic, not interventional.

The practical question is what you do with the result. A zero or low score on a person with no diabetes and no family history supports a decision to avoid statins. A high score in any person makes the case for aggressive lifestyle changes and statin therapy much stronger, because it shows actual disease is present.

Consider an AI-driven metric called the liver attenuation index (LAI), derived from the same CT scan, which predicted future diabetes over 19 years of follow-up in non-obese adults, independent of the CAC score itself [12]. This means one scan can give you your heart risk, your liver fat burden, and your diabetes risk in a single sitting.

My call: If you are between 40 and 75, have at least one risk factor (high cholesterol, high blood pressure, diabetes, smoking, or a strong family history of early heart disease), and you want to know whether you truly have silent plaque in your arteries, this is the single best noninvasive test available. The evidence is strong and independent. The test is cheap (often $100-200 without insurance) and involves a tiny radiation dose (about the same as a mammogram). Do not get a CAC test if you already have known heart disease, have had a stent or bypass, or are under 40 with no risk factors, because the low prevalence of calcium in that group makes a zero score less informative.